放射剂量对头颈部髓外浆细胞瘤局部控制与生存的影响
该研究回顾了2005年1月至2017年1月在本机构接受放疗的27例头颈部髓外浆细胞瘤(EMP)患者,共33个放疗疗程,中位剂量45 Gy(范围12-55.8 Gy)。原发EMP的局部控制率(93% vs 61%,P<0.05)和完全缓解率(67% vs 22%,P<0.01)均优于继发性EMP病变。高剂量(>45 Gy)组中位生存显著长于低剂量(≤45 Gy)组(P=0.02),但原发EMP亚组中高剂量与低剂量在总缓解率、局部控制时长和生存上均无显著差异。
要点
- 原发EMP的局部控制率93%、完全缓解率67%,均显著优于继发性EMP病变(61%、22%)。
- 高剂量(>45 Gy)组中位生存显著长于低剂量(≤45 Gy)组(P=0.02)。
- 原发EMP亚组中高剂量与低剂量在总缓解率、局部控制时长和生存上均无显著差异。
核心结论
- 放疗是治疗髓外浆细胞瘤的有效手段。
- ≤45 Gy的放射剂量可获得与高剂量方案相当的完全缓解率,似乎能有效控制局部EMP进展。
- 放射剂量提升可能对特定亚组患者有益。
研究设计与样本
- 回顾性分析2005年1月至2017年1月在本机构接受放疗的27例头颈部髓外浆细胞瘤患者,共33个放疗疗程,中位年龄56岁,中位放疗剂量45 Gy(范围12-55.8 Gy)。
主要发现
- 局部控制率为76%(原发EMP 93% vs 继发性EMP病变61%;P<0.05)。
- 局部放疗的完全缓解率为42%(原发EMP 67% vs 继发性EMP病变22%;P<0.01)。
- 高剂量(>45 Gy)组与低剂量(≤45 Gy)组的总缓解率分别为87%和67%(P=0.2)。
- 高剂量放疗组的中位生存显著更长(P=0.02)。
- 原发EMP亚组中,高剂量组与低剂量组的总缓解率分别为100%和80%(P=0.3),局部控制时长(P=0.3)和生存(P=0.05)均无显著差异;继发性EMP患者中,高剂量组与低剂量组的总缓解率分别为60%和62%(P=1),生存(P=0.4)无显著差异。
临床怎么用
- 原文结论认为放疗是治疗EMP的有效手段,≤45 Gy的剂量可获得与高剂量方案相当的完全缓解率,似乎能有效控制局部EMP进展。
- 原文结论提出放射剂量提升可能对特定亚组患者有益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with plasma-cell neoplasia usually suffer from systemic disease, although a minority (< 5%) may present with solitary involvement of bone or soft tissue (extramedullary plasmacytoma (EMP)). Radiotherapy (RT) is a state-of-the-art treatment for these tumors offering long term curation. METHODS AND MATERIALS: Between January 2005 and January 2017, twenty-seven patients underwent RT at our institution. The aim of this study was to analyse the effectiveness of various RT doses for different forms of EMP. RESULTS: A total of 33 radiation courses were administered to 27 patients with a median age of 56 years. The median RT dose was 45 Gy (range: 12-55.8). The local control rate was 76% (93% for primary EMP vs. 61% for the secondary EMP lesions; P < 0.05). A complete response (CR) rate to local RT was achieved for 42% lesions (67% for primary EMP vs. 22% for the secondary EMP lesions; P < 0.01). The overall response rate (ORR) for the EMP lesions treated with high-dose regimens (> 45 Gy) versus low-dose regimens (≤ 45 Gy) was 87% versus 67%, respectively (P = 0.2). The median survival with high-dose RT group was significantly longer (P = 0.02). In subgroups analysis, primary EMP patients treated with high-dose RT had a non-significant higher ORR (100% vs. 80%, respectively; P = 0.3,) longer duration of LC (P = 0.3) with a longer survival (P = 0.05) than patients in low-dose group. No significant difference has been detected in secondary EMP patients treated with high-dose RT regarding ORR (60% vs. 62%, respectively; P = 1), and survival (P = 0.4). CONCLUSION: RT is an efficacious treatment modality in the treatment of EMP. A radiation dose ≤45 Gy confer a comparable CR rate to high-dose regimens and appears to be an effective treatment for controlling local EMP progression. Radiation dose-escalation may be beneficial for particular subgroups of patients.
引用
- Oertel M, Elsayad K, Kroeger KJ, et al. Impact of radiation dose on local control and survival in extramedullary head and neck plasmacytoma. Radiat Oncol. 2019. PMID: 30987659. doi:10.1186/s13014-019-1265-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。